134 related articles for article (PubMed ID: 30845102)
21. Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia.
McBride A; Nayak P; Kreychman Y; Todd L; Duliege AM; Mehta AR
Am J Manag Care; 2019 Nov; 25(19 Suppl):S347-S358. PubMed ID: 31809006
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
23. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Okamoto H; Kobayashi A
N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
[No Abstract] [Full Text] [Related]
24. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
25. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
26. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.
Herman SE; Barr PM; McAuley EM; Liu D; Wiestner A; Friedberg JW
Leukemia; 2013 Aug; 27(8):1769-73. PubMed ID: 23385377
[No Abstract] [Full Text] [Related]
27. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
28. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Martin P; Gillen M; Ritter J; Mathews D; Brealey C; Surry D; Oliver S; Holmes V; Severin P; Elsby R
Drugs R D; 2016 Mar; 16(1):93-107. PubMed ID: 26748647
[TBL] [Abstract][Full Text] [Related]
29. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
30. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Kunwar S; Devkota AR; Ghimire DK
Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
[TBL] [Abstract][Full Text] [Related]
31. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
[TBL] [Abstract][Full Text] [Related]
32. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
33. Healing the Syk through kinase inhibitors.
Rivera J; Colbert RA
N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
[No Abstract] [Full Text] [Related]
34. Novel small-molecular therapeutics for rheumatoid arthritis.
Fleischmann R
Curr Opin Rheumatol; 2012 May; 24(3):335-41. PubMed ID: 22357358
[TBL] [Abstract][Full Text] [Related]
35. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy.
Kapur R
Br J Haematol; 2020 Sep; 190(6):817-818. PubMed ID: 32656765
[No Abstract] [Full Text] [Related]
36. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
37. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Otón T; Silva-Fernández L; Andreu JL
N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
[No Abstract] [Full Text] [Related]
38. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.
Opar A
Nat Rev Drug Discov; 2010 Apr; 9(4):257-8. PubMed ID: 20357793
[No Abstract] [Full Text] [Related]
39. Current treatment options for primary immune thrombocytopenia.
Salama A
Expert Rev Hematol; 2011 Feb; 4(1):107-18. PubMed ID: 21322783
[TBL] [Abstract][Full Text] [Related]
40. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]